Vol. 19/No. 23

Some immune-related adverse events associated with immune checkpoint inhibitor therapies may prove to be higher than the data reported in the trials that led to the drugs’ initial FDA approval.

Consciously or unconsciously, all oncologists develop some sort of system for managing the growing complexity of cancer care.

The frequency of hereditary mutations that convey an increased risk of ovarian cancer suggests that many cases of the disease are preventable.

A growing understanding about the underlying biology of myelofibrosis has helped improve the diagnosis and treatment of the disease during the past decade and is paving the way for further advancements.

Vivek Venkatramani, MD, and Dipen J. Parekh, MD, discuss the evolution of surgery in bladder cancer.

Over the past 30 years, from the discovery of a fusion rearrangement to the recent promise of LOXO-292, RET targeting has gone from distant concept toward clinical reality.

Although he held a longtime fascination with space exploration to the moon and Mars, Daniel P. Petrylak, MD, took a different path and broke new ground in another frontier: genitourinary oncology.

Since the introduction of platinum agents in ovarian cancer, it is reasonable to suggest there have been only limited changes in the basic paradigm of ovarian cancer management over the past several decades.

Although many new drugs have been introduced for treating patients with hematologic malignancies, stem cell transplantation remains a vital part of the therapeutic paradigm, particularly for multiple myeloma and non-Hodgkin lymphoma.

In contrast to the wide array of available therapies in the metastatic setting of renal cell carcinoma, in patients with localized disease, the results of trials investigating adjuvant systemic therapy after nephrectomy have so far been underwhelming.

Investigators are optimistic about sacituzumab govitecan (IMMU-132), an antibody–drug conjugate that delivers the chemotherapy metabolite SN-38 to tumor cells expressing the TROP-2 receptor, for patients with relapsed/refractory TNBC.

Maurie Markman, MD, discusses the steps that the scientific community needs to take to increase public acceptance of the vaccine against the human papillomavirus.